Abstract

PurposeAlterations in brain glucose metabolism detected by 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) positron emission tomography (PET) may serve as an early predictive biomarker and treatment target for epileptogenesis. Here, we aimed to investigate changes in cerebral glucose metabolism before induction of epileptogenesis, during epileptogenesis as well as during chronic epilepsy. As anesthesia is usually unavoidable for preclinical PET imaging and influences the distribution of the radiotracer, four different protocols were compared.ProceduresWe investigated 18F-FDG uptake phase in conscious rats followed by a static scan as well as dynamic scans under continuous isoflurane, medetomidine-midazolam-fentanyl (MMF), or propofol anesthesia. Furthermore, we applied different analysis approaches: atlas-based regional analysis, statistical parametric mapping, and kinetic analysis.ResultsAt baseline and compared to uptake in conscious rats, isoflurane and propofol anesthesia resulted in decreased cortical 18F-FDG uptake while MMF anesthesia led to a globally decreased tracer uptake. During epileptogenesis, MMF anesthesia was clearly best distinctive for visualization of prominently increased glucometabolism in epilepsy-related brain areas. Kinetic modeling further increased sensitivity, particularly for continuous isoflurane anesthesia. During chronic epilepsy, hypometabolism affecting more or less the whole brain was detectable with all protocols.ConclusionThis study reveals evaluation of anesthesia protocols for preclinical 18F-FDG PET imaging as a critical step in the study design. Together with an appropriate data analysis workflow, the chosen anesthesia protocol may uncover otherwise concealed disease-associated regional glucometabolic changes.

Highlights

  • With approximately 50 million affected people worldwide, epilepsy is one of the most common chronic neurological diseases [1]

  • Hypometabolism affecting more or less the whole brain was detectable with all protocols

  • This study reveals evaluation of anesthesia protocols for preclinical 18F-FDG positron emission tomography (PET) imaging as a critical step in the study design

Read more

Summary

Introduction

With approximately 50 million affected people worldwide, epilepsy is one of the most common chronic neurological diseases [1] It is characterized by an excessive neuronal network activity leading to the generation of spontaneous recurrent seizures [2]. Detection of the radiolabeled glucose analogue 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) by positron emission tomography (PET) is well established to image in vivo brain glucose utilization in clinical and preclinical studies [3, 4]. Using this method, focal interictal glucose hypometabolism is a widely detectable phenomenon in chronic epileptic patients [4]. Alterations in brain glucose metabolism detected by 18F-FDG PET may serve as an early predictive biomarker and treatment target for post-brain insult epileptogenesis [12, 13]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call